Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-26 00:05 | 2026-02-23 | IRWD | IRONWOOD PHARMACEUTICALS INC | Shetzline Michael | Officer | SELL | $3.73 | 32,582 | $121,586 | 521,425 |
| 2026-02-26 00:05 | 2026-02-23 | IRWD | IRONWOOD PHARMACEUTICALS INC | Gaskins Tammi L | Officer | SELL | $3.73 | 21,526 | $80,329 | 213,738 |
| 2026-02-26 00:05 | 2026-02-23 | IRWD | IRONWOOD PHARMACEUTICALS INC | MCCOURT Thomas A | Director, Officer | SELL | $3.73 | 198,283 | $739,933 | 1,489,002 |
| 2026-02-26 00:05 | 2026-02-23 | IRWD | IRONWOOD PHARMACEUTICALS INC | Silver Ronald | Officer | SELL | $3.73 | 24,173 | $90,206 | 252,636 |
| 2026-02-26 00:13 | 2026-02-24 | ARDX | Ardelyx Inc. | RAAB MICHAEL | Director, Officer | OPT+S | $6.26 | 41,666 | $260,621 | 1,836,153 |
| 2026-02-26 00:04 | 2026-02-24 | INSM | INSMED Inc | Smith Michael Alexander | Officer | OPT+S | $155.77 | 24,774 | $3,859,157 | 51,871 |
| 2026-02-26 00:31 | 2026-02-25 | UTHR | UNITED THERAPEUTICS Corp | CAUSEY CHRISTOPHER | Director | OPT+S | $520.00 | 1,000 | $520,000 | 4,190 |
| 2026-02-26 03:58 | 2026-02-23 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Director, Officer | SELL | $41.98 | 16,925 | $710,578 | 257,163 |
| 2026-02-26 03:59 | 2026-02-23 | VERA | Vera Therapeutics, Inc. | Grant Sean | Officer | SELL | $41.98 | 4,949 | $207,778 | 114,181 |
| 2026-02-26 04:00 | 2026-02-23 | VERA | Vera Therapeutics, Inc. | Young Joseph R | Officer | SELL | $41.98 | 3,117 | $130,864 | 64,722 |
| 2026-02-26 04:01 | 2026-02-23 | VERA | Vera Therapeutics, Inc. | Brenner Robert | Officer | SELL | $41.98 | 2,151 | $90,307 | 50,947 |
| 2026-02-26 03:53 | 2026-02-23 | VERA | Vera Therapeutics, Inc. | Skelton Laurence Matthew | Officer | SELL | $41.98 | 1,582 | $66,419 | 64,218 |
| 2026-02-26 03:56 | 2026-02-23 | VERA | Vera Therapeutics, Inc. | Turner William D. | Officer | SELL | $41.98 | 2,187 | $91,819 | 45,313 |
| 2026-02-26 03:57 | 2026-02-23 | VERA | Vera Therapeutics, Inc. | JOHNSON DAVID LEE | Officer | SELL | $41.98 | 2,579 | $108,276 | 45,727 |
| 2026-02-26 02:17 | 2026-02-23 | OCUL | OCULAR THERAPEUTIX, INC | Nayak Sanjay | Officer | SELL | $8.28 | 1,759 | $14,565 | 330,653 |
| 2026-02-26 02:18 | 2026-02-23 | OCUL | OCULAR THERAPEUTIX, INC | Heier Jeffrey S. | Officer | SELL | $8.28 | 3,057 | $25,312 | 323,368 |
| 2026-02-26 02:19 | 2026-02-23 | OCUL | OCULAR THERAPEUTIX, INC | Kaiser Peter | Officer | SELL | $8.28 | 2,810 | $23,267 | 269,108 |
| 2026-02-26 02:20 | 2026-02-23 | OCUL | OCULAR THERAPEUTIX, INC | Dugel Pravin | Director, Officer | SELL | $8.28 | 20,056 | $166,064 | 3,013,022 |
| 2026-02-26 01:08 | 2026-02-23 | ARVN | Arvinas Inc. | Teel Randy | Director, Officer | SELL | $12.16 | 4,786 | $58,198 | 149,696 |
| 2026-02-26 01:09 | 2026-02-23 | ARVN | Arvinas Inc. | Cacace Angela M | Officer | SELL | $12.16 | 3,609 | $43,885 | 147,623 |
| 2026-02-26 01:09 | 2026-02-23 | ARVN | Arvinas Inc. | Loomis David K | Officer | SELL | $12.16 | 1,108 | $13,473 | 29,692 |
| 2026-02-26 00:08 | 2026-02-23 | RPRX | Royalty Pharma plc | Coyne Terrance P. | Officer | SELL | $45.32 | 34,791 | $1,576,606 | 47,636 |
| 2026-02-26 00:10 | 2026-02-24 | COCP | Cocrystal Pharma, Inc. | FROST PHILLIP MD ET AL | Director, 10% owner | BUY | $1.00 | 20,000 | $19,952 | 1,908,551 |
| 2026-02-25 15:00 | 2026-02-23 | LXRX | LEXICON PHARMACEUTICALS, INC. | DEBBANE RAYMOND | Director | BUY | $1.47 | 100,000 | $147,000 | 1,904,186 |
| 2026-02-25 00:05 | 2026-02-20 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | Director, Officer | OPT+S | $30.10 | 60,000 | $1,805,766 | 432,886 |
| 2026-02-25 00:31 | 2026-02-23 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $472.13 | 14,440 | $6,817,499 | 0 |
| 2026-02-25 03:42 | 2026-02-23 | KALV | KalVista Pharmaceuticals, Inc. | Piekos Brian | Officer | OPT+S | $15.57 | 1,767 | $27,507 | 13,762 |
| 2026-02-25 03:42 | 2026-02-23 | KALV | KalVista Pharmaceuticals, Inc. | Sweeny Nicole | Officer | OPT+S | $15.57 | 3,975 | $61,878 | 47,003 |
| 2026-02-25 03:43 | 2026-02-23 | KALV | KalVista Pharmaceuticals, Inc. | Yea Christopher | Officer | OPT+S | $15.57 | 4,347 | $67,669 | 226,701 |
| 2026-02-25 03:44 | 2026-02-23 | KALV | KalVista Pharmaceuticals, Inc. | Palleiko Benjamin L | Director, Officer | OPT+S | $15.57 | 10,034 | $156,197 | 442,883 |
| 2026-02-25 03:44 | 2026-02-23 | KALV | KalVista Pharmaceuticals, Inc. | Audhya Paul K. | Officer | OPT+S | $15.57 | 5,354 | $83,345 | 138,983 |
| 2026-02-25 02:57 | 2026-02-20 | MPLT | MapLight Therapeutics, Inc. | Malenka Robert C. | Director | SELL | $18.34 | 14,195 | $260,399 | 325,059 |
| 2026-02-25 02:13 | 2026-02-20 | OCUL | OCULAR THERAPEUTIX, INC | LINDSTROM RICHARD L MD | Director | BUY | $7.66 | 60,229 | $461,354 | 246,933 |
| 2026-02-25 02:13 | 2026-02-20 | OCUL | OCULAR THERAPEUTIX, INC | Waheed Nadia | Officer | SELL | $7.74 | 3,510 | $27,167 | 314,907 |
| 2026-02-25 00:58 | 2026-02-20 | RIGL | RIGEL PHARMACEUTICALS INC | MOOS WALTER H | Director | OPT+S | $36.36 | 4,000 | $145,440 | 12,722 |
| 2026-02-25 00:40 | 2026-02-20 | NAMS | NewAmsterdam Pharma Co N.V. | Kastelein Johannes Jacob Pieter | Director, Officer | SELL | $35.31 | 45,481 | $1,605,998 | 53,500 |
| 2026-02-25 00:28 | 2026-02-23 | VNDA | Vanda Pharmaceuticals Inc. | Honore Tage | Director | SELL | $8.03 | 30,000 | $240,900 | 93,469 |
| 2026-02-24 00:32 | 2026-02-19 | BBIO | BridgeBio Pharma, Inc. | Kumar Neil | Director, Officer | SELL | $71.39 | 28,053 | $2,002,718 | 234,451 |
| 2026-02-24 00:21 | 2026-02-19 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Sachdev Amit | Officer | OPT+S | $468.83 | 58,613 | $27,479,586 | 58,934 |
| 2026-02-24 00:34 | 2026-02-19 | INSM | INSMED Inc | Lewis William | Director, Officer | OPT+S | $150.97 | 10,699 | $1,615,257 | 301,185 |
| 2026-02-24 05:01 | 2026-02-20 | ARDX | Ardelyx Inc. | MOTT DAVID M | Director | BUY | $5.84 | 333,333 | $1,946,331 | 3,302,918 |
| 2026-02-24 04:45 | 2026-02-20 | ARDX | Ardelyx Inc. | Kelliher Mike | Officer | SELL | $5.85 | 9,595 | $56,099 | 364,666 |
| 2026-02-24 04:46 | 2026-02-20 | ARDX | Ardelyx Inc. | Brady James Parker | Officer | SELL | $5.85 | 2,543 | $14,868 | 262,912 |
| 2026-02-24 04:47 | 2026-02-20 | ARDX | Ardelyx Inc. | Hohenleitner Susan | Officer | SELL | $5.85 | 2,033 | $11,886 | 230,533 |
| 2026-02-24 04:47 | 2026-02-20 | ARDX | Ardelyx Inc. | Williams Laura A | Officer | SELL | $5.85 | 8,176 | $47,803 | 436,082 |
| 2026-02-24 04:54 | 2026-02-20 | ARDX | Ardelyx Inc. | Reilly Joseph James | Officer | SELL | $5.85 | 4,991 | $29,181 | 151,790 |
| 2026-02-24 04:54 | 2026-02-20 | ARDX | Ardelyx Inc. | Bishop John E | Officer | SELL | $5.85 | 3,179 | $18,586 | 339,151 |
| 2026-02-24 04:40 | 2026-02-19 | ROIV | Roivant Sciences Ltd. | Torti Frank | Officer | OPT+S | $27.35 | 3,000,000 | $82,039,500 | 13,736,547 |
| 2026-02-24 04:45 | 2026-02-20 | ARDX | Ardelyx Inc. | Foster Eric Duane | Officer | SELL | $5.85 | 10,439 | $61,034 | 425,970 |
| 2026-02-24 04:45 | 2026-02-20 | ARDX | Ardelyx Inc. | RAAB MICHAEL | Director, Officer | SELL | $5.85 | 45,982 | $268,838 | 1,856,986 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.